ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson’s Disease Read more about ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson’s Disease
ZyVersa Therapeutics Adds Dr. Douglas Golenbock to Its Inflammatory Disease Scientific Advisory Board to Support Advancement of Inflammasome ASC Inhibitor IC 100 Read more about ZyVersa Therapeutics Adds Dr. Douglas Golenbock to Its Inflammatory Disease Scientific Advisory Board to Support Advancement of Inflammasome ASC Inhibitor IC 100
ZyVersa Therapeutics Announces Article Published in Biomaterials Addressing the Critical Role of Inflammasome Activation in Neuroinflammation Resulting from Intracortical Implants Read more about ZyVersa Therapeutics Announces Article Published in Biomaterials Addressing the Critical Role of Inflammasome Activation in Neuroinflammation Resulting from Intracortical Implants
ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimer’s Disease Read more about ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimer’s Disease
ZyVersa Therapeutics’ CEO, Stephen C. Glover to Appear on Benzinga 'All Access' Read more about ZyVersa Therapeutics’ CEO, Stephen C. Glover to Appear on Benzinga 'All Access'
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Planet MicroCap Showcase Read more about ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Planet MicroCap Showcase
ZyVersa Therapeutics Announces Article Published in Brain Pathology Addressing Inflammasome Signaling Proteins in Alzheimer’s Disease Read more about ZyVersa Therapeutics Announces Article Published in Brain Pathology Addressing Inflammasome Signaling Proteins in Alzheimer’s Disease
ZyVersa Therapeutics Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results Read more about ZyVersa Therapeutics Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results
ZyVersa Therapeutics Reports New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about ZyVersa Therapeutics Reports New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZyVersa Therapeutics Adds Dr. Richard J. Glassock to Its Renal Scientific Advisory Board to Support Clinical Advancement of Renal Cholesterol Efflux Mediator™ VAR 200 Read more about ZyVersa Therapeutics Adds Dr. Richard J. Glassock to Its Renal Scientific Advisory Board to Support Clinical Advancement of Renal Cholesterol Efflux Mediator™ VAR 200
